Division of Gene Therapy Science, Graduate School of Medicine, Osaka University, Japan.
BMB Rep. 2010 Dec;43(12):773-80. doi: 10.5483/BMBRep.2010.43.12.773.
Cancers are still difficult targets despite recent advances in cancer therapy. Due to the heterogeneity of cancer, a single-treatment modality is insufficient for the complete elimination of cancer cells. Therapeutic strategies from various aspects are needed. Gene therapy has been expected to bring a breakthrough to cancer therapy, but it has not yet been successful. Gene therapy also should be combined with other treatments to enhance multiple therapeutic pathways. In this view, gene delivery vector itself should be equipped with intrinsic anti-cancer activities. HVJ (hemagglutinating virus of Japan; Sendai virus) envelope vector (HVJ-E) was developed to deliver therapeutic molecules. HVJ-E itself possessed anti-tumor activities such as the generation of anti-tumor immunities and the induction of cancer-selective apoptosis. In addition to the intrinsic anti-tumor activities, therapeutic molecules incorporated into HVJ-E enabled to achieve multi-modal therapeutic strategies in cancer treatment. Tumor-targeting HVJ-E was also developed. Thus, HVJ-E will be a novel promising tool for cancer treatment.
尽管癌症治疗最近取得了进展，但癌症仍然是难以攻克的目标。由于癌症的异质性，单一的治疗方式不足以完全消除癌细胞。需要从多个方面制定治疗策略。基因治疗有望为癌症治疗带来突破，但尚未成功。基因治疗也应该与其他治疗方法相结合，以增强多种治疗途径。从这个角度来看，基因传递载体本身应该具有内在的抗癌活性。日本血凝病毒（HVJ；仙台病毒）包膜载体（HVJ-E）被开发用于传递治疗分子。HVJ-E 本身具有抗肿瘤活性，如产生抗肿瘤免疫和诱导癌症选择性凋亡。除了内在的抗肿瘤活性外，将治疗分子掺入 HVJ-E 中还能够实现癌症治疗的多模式治疗策略。肿瘤靶向 HVJ-E 也已被开发出来。因此，HVJ-E 将成为癌症治疗的一种有前途的新型工具。
